Search Results for: US Stem Cell

Take-homes from new FDA NEJM stem cell piece including surprises

Peter-Marks-Scott-Gottlieb-FDA

FDA Commissioner Scott Gottlieb and CBER Director, Peter Marks, have just published a new piece on stem cells and regenerative medicine in the New England Journal of Medicine (NEJM). What are the core points here and what can we learn from reading between the lines a bit? There are some expected things and then some […]

Take-homes from new FDA NEJM stem cell piece including surprises Read More »

Just one word placentas: Can Celularity live up to hype?

Celularity-e1519061558939

I’ve been blogging about stem cells now for about 8 years and the recent level of hype about and fluffy media coverage of Celularity, the biotech spun out of Celgene, ranks right up here with the most extreme past cases I’ve seen. What is Celularity and who is its leadership? It’s a new biotech focused

Just one word placentas: Can Celularity live up to hype? Read More »

TGIF: Guns, stem cells, science weekends reads & good news

Wakabayashi-et-al.-Cell-Stem-Cell-Figure-1F

I’ve got some TGIF recommend reads on stem cells, etc, but first, what a week, right? We need more action on preventing gun violence. It’s a uniquely American health crisis that doesn’t have to be. There’s no real, common sense reason that gun control can’t reduce mass killings of our kids and others like the

TGIF: Guns, stem cells, science weekends reads & good news Read More »

Pending State Medical Boards Group Report on Stem Cell Clinics Could be Game Changer

State-Medical-Boards-stem-cell-draft-recommendations

We have a big problem with clinics in the U.S. selling unproven and non-FDA approved stem cell “treatments” to patients and part of the reason in my view why we have this mess today with upwards of 700 such businesses from coast to coast is that regulators including both the FDA and state medical boards

Pending State Medical Boards Group Report on Stem Cell Clinics Could be Game Changer Read More »

Washington State Bill to Require Unproven Stem Cell Clinics to Post Notices

Charles-Murry-UW

There’s some also encouraging action at the state level on direct-to-consumer stem cell clinics operating without FDA approval including most recently in Washington State. Last year here in California we passed a bill into law that (1) requires stem cell clinics selling non-FDA approved therapies to post notices for patients and (2) instructs the state medical

Washington State Bill to Require Unproven Stem Cell Clinics to Post Notices Read More »

Why did Texas A&M ink big deal with stem cell clinic firm Celltex on exosomes?

Texas-AM-Celltex-deal

The recent news that Texas A&M University has inked a full-blown deal with the direct-to-consumer stem cell clinic firm Celltex struck me as an unusual development. Recently we’ve seen more universities exploring the use of stem cells outside of the traditional FDA clinical trial process that is fundamentally based on an investigational new drug application (IND). Some

Why did Texas A&M ink big deal with stem cell clinic firm Celltex on exosomes? Read More »

Internecine conflicts among direct-to-consumer stem cell firms

Regenexx-blog

Stem cell clinics marketing non-FDA approved therapies directly to consumers have been in various tense situations at times with the FDA or academics over the years, but more recently these stem cell clinic-related firms also appear in conflict with each other sometimes. The most notable recent example of conflict involves Dr. Christopher Centeno of Regenexx

Internecine conflicts among direct-to-consumer stem cell firms Read More »

Stem cells for the flu? Pondering PR email, frailty data from Longeveron

Tompkins-Figure-2A

Stem cells for flu? For me, that idea is new. Some months back there was buzz about the stem cell biotech Longeveron related to its report on early trial data on testing infusions of mesenchymal stem cells for frailty in the aged. Frailty that pops up in some aging folks can manifest in a variety

Stem cells for the flu? Pondering PR email, frailty data from Longeveron Read More »